ES2581565T3 - Aminotriazolopiridinas y su uso como inhibidores de cinasas - Google Patents
Aminotriazolopiridinas y su uso como inhibidores de cinasas Download PDFInfo
- Publication number
- ES2581565T3 ES2581565T3 ES09789271.5T ES09789271T ES2581565T3 ES 2581565 T3 ES2581565 T3 ES 2581565T3 ES 09789271 T ES09789271 T ES 09789271T ES 2581565 T3 ES2581565 T3 ES 2581565T3
- Authority
- ES
- Spain
- Prior art keywords
- pyridin
- triazolo
- ylamino
- methyl
- indazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Virology (AREA)
Abstract
Un compuesto de fórmula (I):**Fórmula** o una sal, tautómero, estereoisómero o solvato farmacéuticamente aceptable del mismo, en donde: 5 R1 es un arilo sustituido o sin sustituir o un heterociclilo sustituido o sin sustituir; R2 es un alquilo C1-8 sustituido o sin sustituir, un cicloalquilo sustituido o sin sustituir, un heterociclilalquilo sustituido o sin sustituir, un aralquilo sustituido o sin sustituir, -OR3, -C(>=O)R5, -C(>=O)NR3R4, -NHC(>=O)R3, - (CH2)0-2CR6(OR3)R4 o un heterociclilo sustituido o sin sustituir seleccionado de 1,2,3,6-tetrahidropiridilo, bencisoxazolilo o isoindolin-1-onilo. R3 y R4 son cada vez que aparecen, independientemente, -H, un alquilo C1-8 sustituido o sin sustituir, un arilo sustituido o sin sustituir, un heteroarilo sustituido o sin sustituir, un cicloalquilo sustituido o sin sustituir, un heterociclilo sustituido o sin sustituir, un aralquilo sustituido o sin sustituir o un heterociclilalquilo sustituido o sin sustituir; R5 es alquilo C1-8 sustituido o sin sustituir, un arilo sustituido o sin sustituir, un heteroarilo sustituido o sin sustituir, un cicloalquilo sustituido o sin sustituir, un heterociclilo sustituido o sin sustituir, un aralquilo sustituido o sin sustituir o un heterociclilalquilo sustituido o sin sustituir; y R6 es -H, o un alquilo C1-8 sustituido o sin sustituir, o junto con R4 y los átomos a los que están unidos forman un heterociclilo sustituido o sin sustituir.
Description
5
10
15
20
25
30
35
y sales farmacéuticamente aceptables, tautómeros, estereoisómeros y solvatos de los mismos, en donde:
R1 es un arilo sustituido o sin sustituir o un heterociclilo sustituido o sin sustituir;
R2 es un alquilo C1-8 sustituido o sin sustituir, un cicloalquilo sustituido o sin sustituir, un heterociclilalquilo sustituido o sin sustituir, un aralquilo sustituido o sin sustituir, -NR3R4, -OR3, -C(=O)R5, -C(=O)NR3R4, -NHC(=O)R3, -(CH2)02CR6(OR3)R4, o un heterociclilo sustituido o sin sustituir seleccionado de 1,2,3,6-tetrahidropiridilo, bencisoxazolilo o isoindolin-1-onilo.
R3 y R4 son cada vez que aparecen, independientemente, -H, un alquilo C1-8 sustituido o sin sustituir, un arilo sustituido o sin sustituir, un heteroarilo sustituido o sin sustituir, un cicloalquilo sustituido o sin sustituir, un heterociclilo sustituido o sin sustituir, un aralquilo sustituido o sin sustituir o un heterociclilalquilo sustituido o sin sustituir;
R5 es alquilo C1-8 sustituido o sin sustituir, un arilo sustituido o sin sustituir, un heteroarilo sustituido o sin sustituir, un cicloalquilo sustituido o sin sustituir, un heterociclilo sustituido o sin sustituir, un aralquilo sustituido o sin sustituir o un heterociclilalquilo sustituido o sin sustituir; y
R6 es -H, o un alquilo C1-8 sustituido o sin sustituir, o junto con R4 y los átomos a los que están unidos forman un heterociclilo sustituido o sin sustituir.
En una realización, el compuesto de heteroarilo es un compuesto de fórmula (I), en donde R1 es un arilo sustituido o sin sustituir, por ejemplo, un fenilo sustituido o sin sustituir. En algunas de dichas realizaciones, R1 es fenilo, sustituido con uno o más de alquilo C1-4 sustituido o sin sustituir, heterociclilo sustituido o sin sustituir, halógeno, hidroxilo, alcoxi, carboxi, -CN, -(alquil C0-4)NR2, -O(alquil C1-4)NR2, -NR2, o -C(=O)NR2, en donde cada R es independientemente H, un alquilo C1-6 sustituido o sin sustituir, o un heterociclilo sustituido o sin sustituir. Por ejemplo, en ciertas realizaciones, R1 es fenilo, sustituido con uno o más de -F, -Cl, -CF3, -CN, hidroxi, carboxi, metilo, -(alquil C0-4)NH2, -(alquil C0-4)NH(alquilo C1-4), -O(alquilo C1-4), -O(alquil C1-4)O(alquilo C1-4), -O(alquil C1-4)NH2, N(alquilo C1-4)2, -C(=O)NH2, -C(=O)NH(alquilo C1-4), -C(=O)NH(piperidilo sustituido o sin sustituir) o un heterociclilo sustituido o sin sustituir seleccionado de morfolinilo, triazolilo, pirrolidilo, imidazolilo o pirrolidinonilo.
En algunas realizaciones, el compuesto de heteroarilo es un compuesto de fórmula (I), en donde R1 es un heterociclilo sustituido o sin sustituir. Por ejemplo, en ciertas realizaciones, R1 es un heterociclilo sustituido o sin sustituir seleccionado de isoindolin-1-onilo, piridilo, pirimidilo, indazolilo, indolinilo, isoindolinilo, indolin-2-onilo, quinolinilo, dihidroisoquinolin-1-onilo, benzotriazolilo, bencimidazolilo, 1H-pirazolo[3,4-b]piridilo, 1H-pirazolo[4,3b]piridilo, 1H-benzo[d]imidazol-2(3H)-onilo, benzoisoxazolilo, isoquinolinilo, dihidrobencisotiazol-1,1-dionilo o pirrolopiridilo. En algunas de dichas realizaciones, R1 está sustituido con uno o más de alquilo C1-4 sustituido o sin sustituir, heterociclilo sustituido o sin sustituir, halógeno, hidroxilo, hidroxialquilo, alcoxi, -CN, -OR, -NR2, -(alquil C14)NR2, -C(=O)NR2 o -C(O)R, en donde cada R es independientemente -H, un alquilo C1-6 sustituido o sin sustituir, un heterociclilo sustituido o sin sustituir o un heterociclilalquilo sustituido o sin sustituir.
En algunas de dichas realizaciones, R1 es
10
5
10
15
20
25
30
35
En algunas realizaciones, R' es -H, -CH3, -CH2CH3, isopropilo, -(CH2)2OH, -(CH2)2NH2 o -(CH2)2OCH3. En otras realizaciones, R" es -F, -CH3, -CH2CH3, isopropilo, -NH(alquil C1-3)NH2, -NH(CH2)2OH, -CF3, -OH, -OCH3, O(CH2)2OCH3, -O(CH2)2OH, -O(CH2)2NH2, -O(CH2)2pirrolidilo, -CH2OH, -(CH2)2OH, -CH2OCH3, -(CH2)2OCH3, -CH2NH2, -CH2NHCH3, -CH2N(CH3)2, -C(CH3)2OH, -CN, -NH2, -NHCH3, -N(CH3)2, -NH(CH2)2NH2, -C(=O)NH2, C(=O)NHCH3, -NH(CH2)2pirrolidilo, -NH(piperidilo sustituido o sin sustituir), piperidilo sustituido o sin sustituir, NH(tetrahidropiranilo sustituido o sin sustituir) o morfolinilo sustituido o sin sustituir.
En algunas realizaciones, el compuesto de heteroarilo es un compuesto de fórmula (I), en donde R2 es un alquilo C16 sustituido o sin sustituir. Por ejemplo, en ciertas realizaciones, R2 es metilo, etilo, n-propilo, isopropilo, n-butilo, secbutilo, isobutilo o terc-butilo, opcionalmente sustituido con uno o más de -OH, -C(O)NH2, -NH2, alquilamino, NHCH2C(=O)NH2, ciclopentilo, ciclopentanol, ciclohexilo, ciclohexanol o 1-metilciclohexanol-4-ilo. En algunas realizaciones, R2 es un cicloalquilo sustituido o sin sustituir, por ejemplo, R2 es ciclohexilo. En otras realizaciones, R2 es un heterociclilalquilo sustituido o sin sustituir, por ejemplo, -CH2-azetidinilo, -CH2-piperidilo, -CH2-piridin-2(1H)onilo, -CH2-piridilo, -CH2-piperazin-2-onilo, -CH2-piperazin-2,6-dionilo, -CH2-piperazinilo, -CH2-pirrolidilo, -CH2-1,4dioxanilo, -CH2-piperidin-2,6-dionilo, -CH2-imidazolidinilo, -CH2-imidazolidin-4-onilo, -CH2-morfolinilo, -CH2tetrahidropirimidin-2(1H)-onilo, -CH2-1,4-diazepan-5-onilo, -CH2-tetrahidro-2H-piranilo o -CH2-imidazolidin-2,4-dionilo; en donde el heterociclilalquilo está opcionalmente sustituido con uno o más de metilo, etilo, isopropilo, halógeno, -OH, -(CH2)OH o -C(=O)NH2. Por ejemplo, en algunas realizaciones, R2 es -CF2-(tetrahidro-2H-piran-4-ilo) o -CF2(1,4-dioxan-2-ilo).
En algunas realizaciones, el compuesto de heteroarilo es un compuesto de fórmula (I), en donde R2 es -NR3R4. Por ejemplo, en ciertas realizaciones, R2 es -NH(alquilo C1-6), -N(alquilo C1-6)2, -N(alquil C1-6)(cicloalquilo), -NH(arilo), NH(heteroarilo), -NH(cicloalquilo), -NH(cicloalquilalquilo), -NH(heterociclilo), -N(alquil C1-6)(heterociclilo) o NH(heterociclilalquilo), en donde cada alquilo, arilo, heteroarilo, cicloalquilo, cicloalquilalquilo, heterociclilo y heterociclilalquilo está independientemente sustituido o sin sustituir. En algunas realizaciones, R2 es -NH(metilo), N(metilo)2, -N(metil)(etilo), -NH(etilo), -NH(propilo), -NH(isopropilo), -NH(ciclopentilo), -NH(ciclohexilo), N(ciclohexil)(metilo), -NHCH2(ciclopentilo), -NHCH2(ciclohexilo), -NH(fenilo), -NH(piridilo), -NH(piperidilo), NH(tetrahidro-2H-piranilo), -N(metil)(tetrahidro-2H-piranilo), -NH(azepanilo), -NH(tetrahidrofuranilo), N(metil)(tetrahidrofuranilo), -NH(pirrolidilo) o -NHCH2(tetrahidro-2H-piranilo), en donde cada metilo, etilo, propilo, isopropilo, ciclopentilo, ciclohexilo, fenilo, piridilo, piperidilo, pirrolidilo, tetrahidro-2H-piranilo, azepanilo o tetrahidrofuranilo está independientemente sustituido o sin sustituir. En algunas de dichas realizaciones, el metilo, etilo, propilo, isopropilo, ciclopentilo, ciclohexilo, fenilo, piridilo, piperidilo, pirrolidilo, tetrahidro-2H-piranilo, azepanilo
o tetrahidrofuranilo, está sustituido con uno o más de fenilo, alquilo C1-4, hidroxialquilo, -NR2, -OR o -C(=O)NR2, en donde cada R es independientemente -H, un alquilo C1-6 sustituido o sin sustituir, un heterociclilo sustituido o sin sustituir o un heterociclilalquilo sustituido o sin sustituir.
En algunas realizaciones, el compuesto de heteroarilo es un compuesto de fórmula (I), en donde R2 es -NHC(=O)R3, en donde R3 es un alquilo C1-4 sustituido o sin sustituir. En otras, R2 es -C(=O)NR3R4, y R3 y R4 son
12
independientemente -H o un alquilo C1-4 sustituido o sin sustituir, o un heterociclilo sustituido o sin sustituir. En otras más, R2 es -OR3. En algunas de dichas realizaciones, R3 es ciclohexilo, metilo, etilo, propilo, piperidilo, tetrahidro-2Hpiranilo, tetrahidrofuranilo, -CH2(pirrolidilo) o fenilo, opcionalmente sustituido con uno o más de -OH, -NH2, o (C=O)NH2. En otras realizaciones más, R2 es -C(=O)R5. Por ejemplo, en ciertas realizaciones, R5 es fenilo.
5 En algunas realizaciones, el compuesto de heteroarilo es un compuesto de fórmula (I), en donde R2 es -(CH2)02CR6(OR3)R4. Por ejemplo, en ciertas realizaciones, R2 es -CH(OR3)R4. En algunas de dichas realizaciones, R3 es -H y R4 es fenilo, piperidilo, piridilo, pirimidin-4(3H)-onilo o tetrahidrofuranilo. En algunas otras realizaciones, R3 es -H y R4 y R6, junto con los átomos a los que están unidos, forman un grupo piperidilo.
En algunas realizaciones, el compuesto de heteroarilo es un compuesto de fórmula (I), en donde R2 es un
10 heterociclilo sustituido o sin sustituir seleccionado de 1,2,3,6-tetrahidropiridilo, bencisoxazolilo o isoindolin-1-onilo. En algunas de dichas realizaciones, R2 está sustituido con uno o más de alquilo C1-4 sustituido o sin sustituir, heterociclilalquilo sustituido o sin sustituir, hidroxilo, -OR, -NR2, o -C(=O)NR2, en donde cada R es independientemente -H, un alquilo C1-6 sustituido o sin sustituir, un heterociclilo sustituido o sin sustituir, o un heterociclilalquilo sustituido o sin sustituir.
15 En algunas realizaciones, R2 es
en donde R' es -H, o un alquilo C1-6 sustituido o sin sustituir; cada R" es independientemente un alquilo C1-4 sustituido o sin sustituir, un heterociclilo sustituido o sin sustituir, un heterociclilalquilo sustituido o sin sustituir,
20 hidroxilo, halógeno, alcoxi, -CN, -OR, -NR2, -(alquil C1-4)NR2, -C(=O)NR2, en donde cada R es independientemente -H, un alquilo C1-6 sustituido o sin sustituir, un heterociclilo sustituido o sin sustituir o un heterociclilalquilo sustituido o sin sustituir; y n = 0-2. Por ejemplo, en ciertas realizaciones, R" es -CH3, -CH2CH3, isopropilo, -CH2OH, -CH2OCH3, -CH(CH3)OH, -(CH2)2NH2, -CH2NHCH3, -CH2N(CH3)2, -OH, -OCH3, -O(CH2)2NH2, -NH2, -NHCH3, -N(CH3)2, -NH(CH2)2OH, -NH(CH2)2NH2, -C(=O)NH2, -CH2(pirrolidilo) o piperazinilo sustituido o sin sustituir.
25 Se entenderá por los expertos en la técnica que cualquiera de los sustituyentes R" puede estar unido a cualquier átomo adecuado de cualquiera de los anillos en los sistemas de anillos condensados. Por ejemplo, en algunas realizaciones, R2 es -(alquilo C1-4), -(alquil C1-4)OH,
13
en donde R' es –H, o un alquilo C1-6 sustituido o sin sustituir; cada R" es independientemente un alquilo C1-4 sustituido o sin sustituir, un heterociclilo sustituido o sin sustituir, un heterociclilalquilo sustituido o sin sustituir, hidroxilo, halógeno, alcoxi, -CN, -OR, -NR2, -(alquil C1-4)NR2, -C(=O)NR2, en donde cada R es independientemente -H, un alquilo C1-6 sustituido o sin sustituir, un heterociclilo sustituido o sin sustituir o un heterociclilalquilo sustituido o sin sustituir; y X = CH2, CF2 o NR'.
En ciertas realizaciones, los compuestos de heteroarilo tienen un grupo R1 expuesto en la presente memoria y un grupo R2 expuesto en la presente memoria. En algunas de dichas realizaciones donde R2 es como se describe en la presente memoria, R1 es
14
(1R,2R)-2-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclopentanol; cis-4-(2-(2-metoxipiridin-4-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; 2-(6-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)-1H-benzo[d]imidazol-2-il)propan-2-ol; 5-(1H-imidazo[4,5-b]piridin-6-il)-N-(4-(trifluorometil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-amina;
5 cis-5-(5-(4-hidroxiciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)picolinonitrilo; cis-4-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)metil)ciclohexanol; trans-1-metil-4-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; cis-1-metil-4-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; cis-2-(4-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexil)propan-2-ol;
10 cis-4-(5-(4-hidroxiciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-N-metilbenzamida; trans-4-(5-(4-hidroxiciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-N-metilbenzamida; 4-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperazin-2-ona; cis-4-(2-(piridin-4-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; cis-4-(2-(5-metilpiridin-3-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol;
15 cis-4-(2-(6-metoxipiridin-3-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; cis-4-(2-(6-(dimetilamino)piridin-3-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; 5-(piperazin-1-ilmetil)-N-(4-(trifluorometil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-amina; trans-4-(5-(4-aminociclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-N-metilbenzamida; 5-(piperidin-4-ilmetil)-N-(4-(trifluorometil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-amina;
20 1-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperidin-4-ol; trans-2-(4-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexil)propan-2-ol; trans-4-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)ciclohexanol; cis-4-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)ciclohexanol; 4-(5-(ciclopentilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-N-metilbenzamida;
25 5-(2-(metoximetil)-1H-benzo[d]imidazol-6-il)-N-(4-(trifluorometil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-amina; 1-(6-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)-1H-benzo[d]imidazol-2-il)etanol; cis-4-(2-(6-metilpiridin-3-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; (S)-N2-(2-(2-aminoetoxi)piridin-4-il)-N5-(piperidin-3-il)-[1,2,4]triazolo[1,5-a]piridin-2,5-diamina; trans-4-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-iloxi)ciclohexanocarboxamida;
30 (1R,2S)-2-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclopentanol; 5-((1-etilpiperidin-4-il)metil)-N-(4-(trifluorometil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-amina; 6-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)-1H-benzo[d]imidazol-2-carboxamida; (6-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)-1H-benzo[d]imidazol-2-il)metanol; cis-(4-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexil)metanol;
35 (S)-N2-(6-morfolinopiridin-3-il)-N5-(piperidin-3-il)-[1,2,4]triazolo[1,5-a]piridin-2,5-diamina; (R)-2-fenil-2-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)etanol; (S)-2-fenil-2-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)etanol;
23
TABLA 1.
Claims (2)
-
imagen1 imagen2 imagen3 imagen4 imagen5 imagen6 3,3,4-trimetil-6-(5-((tetrahidro-2H-piran-4-il)metil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)indolin-2-ona; 4-((2-(2-(metoximetil)-1H-benzo[d]imidazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piridin-2-ol; N-(2-(metoximetil)-1H-benzo[d]imidazol-6-il)-5-((tetrahidro-2H-piran-4-il)metil)-[1,2,4]triazolo[1,5-a]piridin-2-amina; (S)-3,3-dimetil-6-(5-(tetrahidrofuran-3-iloxi)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)indolin-2-ona; (R)-3,3-dimetil-6-(5-(tetrahidrofuran-3-iloxi)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)indolin-2-ona; 1,3,3-trimetil-6-(5-((3-oxopiperazin-1-il)metil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)indolin-2-ona; 3,3-dimetil-6-(5-(piperidin-4-ilmetil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)indolin-2-ona; cis-6-(5-((4-hidroxi-4-metilciclohexil)metil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-3,3-dimetilindolin-2-ona; trans-6-(5-((4-hidroxi-4-metilciclohexil)metil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-3,3-dimetilindolin-2-ona; 1,3,3-trimetil-6-(5-((tetrahidro-2H-piran-4-il)metil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)indolin-2-ona; 2-metil-5-(5-((tetrahidro-2H-piran-4-il)metil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)isoindolin-1-ona; N-(1,4-dimetil-1H-indazol-6-il)-5-((tetrahidro-2H-piran-4-il)metil)-[1,2,4]triazolo[1,5-a]piridin-2-amina; 4-((2-(3-(trifluorometil)-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperazin-2-ona; 3,3-dimetil-6-(5-((2-oxo-1,2-dihidropiridin-4-il)metil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)indolin-2-ona; 5-(5-((2-hidroxipiridin-4-il)metil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)isoindolin-1-ona; 3,3-dimetil-6-(5-(1-(tetrahidro-2H-piran-4-il)etil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)indolin-2-ona; N-(1-metil-1H-indazol-6-il)-5-((tetrahidro-2H-piran-4-il)metil)-[1,2,4]triazolo[1,5-a]piridin-2-amina; (±)-cis-4-(2-(3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-iloxi)tetrahidrofuran-3-ol; 3,3-dimetil-6-(5-(tetrahidro-2H-piran-4-iloxi)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)indolin-2-ona; 3-metil-1-((2-(3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)azetidin-3-ol; 3,3-dimetil-6-(5-((3-oxopiperazin-1-ilmetil))-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)indolin-2-ona; 6-(5-(hidroxi(tetrahidro-2H-piran-4-il)metil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-3,3-dimetilindolin-2-ona; 3,3-dimetil-6-(5-((tetrahidro-2H-piran-4-il)metil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)indolin-2-ona; 4-((2-(3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piridin-2(1H)ona; 5-((3,3-difluoropiperidin-1-il)metil)-N-(3-metil-1H-indazol-6-il)-[1,2,4]triazolo[1,5-a]piridin-2-amina; 2-((2-(3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metilamino)acetamida; cis-1-(metoximetil)-4-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)ciclohexanol; 4-((2-(1-isopropil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperazin-2-ona; 6-(hidroxi(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)pirimidin-4(3H)-ona; N-(3-metil-1H-indazol-6-il)-5-((tetrahidro-2H-piran-4-il)metil)-[1,2,4]triazolo[1,5-a]piridin-2-amina; (2-(3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)(tetrahidro-2H-piran-4-il)metanol; (R)-3-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metilamino)pirrolidin-2-ona; (±)-3-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metilamino)pirrolidin-2-ona; 4-((2-(3-amino-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)ciclohexanol; 4-(1-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)ctil)piridin-2(1H)-ona; N-metil-2-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metilamino)acetamida; 4-(5-((3-hidroxiciclopentil)metil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-N-metilbenzamida (diastereómero 2);3354-((2-(4-fluoro-3-metilfenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piridin-2-ol; 4-((2-(6-(4-hidroxipiperidin-1-il)piridin-3-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperazin-2-ona; (S)-2-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metilamino)propanamida; 4-((2-(4-fluoro-3-metilfenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperazin-2-ona; 4-((2-(1H-pirrolo[2,3-b]piridin-5-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperazin-2-ona; (±)-5-isopropil-4-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperazin-2-ona; 4-(5-((3-hidroxiciclopentil)metil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-N-metilbenzamida (diastereómero1); (±)-2-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metilamino)propanamida; 1-(3-metil-1H-indazol-6-il)-4-((2-(3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperazin-2ona; 4-((2-(3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperazin-2-ona; cis-4-((2-(3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)ciclohexanol; trans-4-((2-(3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)ciclohexanol; 1-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)imidazolidin-2,4-diona; N-metil-4-(5-(2-(piperidin-4-il)etil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)benzamida; 1-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperidin-3-carboxamida; 5-metil-4-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperazin-2-ona; 4-(5-((4-aminociclohexil)metil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-N-metilbenzamida; 4-(1-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)etil)piperazin-2-ona; 4-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperazin-2,6-diona; N-metil-4-(5-(pirrolidin-3-ilmetil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)benzamida; 1-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)-1,4-diazepan-5-ona; (S)-(1-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)pirrolidin-2-il)metanol; (R)-(1-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)pirrolidin-2-il)metanol; (1-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperidin-3-il)metanol; (1-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperidin-4-il)metanol; (S)-3-Metil-4-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperazin-2-ona; N-metil-4-(5-(piperidin-4-ilmetil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)benzamida; 3-metil-4-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperazin-2-ona; 6-metil-4-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)piperazin-2-ona; cis-4-(5-(4-aminociclohexiloxi)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-N-metilbenzamida; N-metil-4-(5-(piperidin-4-iloxi)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)benzamida; 1-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metil)tetrahidropirimidin-2(1H)-ona; 2-((2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)metilamino)acetamida; trans-4-(5-(4-aminociclohexiloxi)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-N-metilbenzamida; 4-(5-(3-hidroxibencil)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-N-metilbenzamida; 5-(2-aminoetoxi)-N-(4-(trifluorometil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-amina;336imagen7 imagen8 imagen9 (R)-3,3-dimetil-6-(5-(tetrahidrofuran-3-ilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)indolin-2-ona; 1,3,3-trimetil-6-(5-(tetrahidro-2H-piran-4-ilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)indolin-2-ona; cis-6-(5-(4-hidroxiciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-1,3,3-trimetilindolin-2-ona; 6-(5-((2-hidroxietil)(metil)amino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-3,3-dimetilindolin-2-ona; (S)-3,3-Dimetil-6-(5-(piperidin-3-ilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)indolin-2-ona; 3,3-dimetil6-(5-(metil(tetrahidro-2H-piran-4-il)amino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)indolin-2-ona; N2-(1-metil-1H-indazol-6-il)-N5-(tetrahidro-2H-piran-4-il)-[1,2,4]triazolo[1,5-a]piridin-2,5-diamina; trans-6-(5-(4-hidroxi-4-metilciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-3,3-dimetilindolin-2-ona; cis-6-(5-(4-hidroxi-4-metilciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-3,3-dimetilindolin-2-ona; cis-4-(2-(4-fluoro-3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; (±)-trans-4-(2-(3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)tetrahidrofurano-3-ol; (R)-N2-(3-metil-1H-indazol-6-il)-N5-(tetrahidrofurano-3-il)-[1,2,4]triazolo[1,5-a]piridin-diamina; 2,5-cis-5-(5-(4-hidroxiciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-2-(2-metoxietil)isoindolin-1-ona; trans-6-(5-(4-hidroxiciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-3,3-dimetilindolin-2-ona; 3,3-dimetil-6-(5-(tetrahidro-2H-piran-4-ilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)indolin-2-ona; (1S,3R)-3-((2-(3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)metil)ciclopentanol; (1R,3R)-3-((2-(3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)metil)ciclopentanol; (1R,3S)-3-((2-(3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)metil)ciclopentanol; (1S,3S)-3-((2-(3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)metil)ciclopentanol; (S)-N2-(3-metil-1H-indazol-6-il)-N5-(tetrahidrofurano-3-il)-[1,2,4]triazolo[1,5-a]piridin-2,5-diamina; cis-6-(5-(4-hidroxiciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-1-(2-hidroxietil)indolin-2-ona; N5-metil-N2-(3-metil-1H-indazol-6-il)-N5-(tetrahidro-2H-piran-4-il)-[1,2,4]triazolo[1,5-a]piridin-2,5-diamina; 2-(metil(2-(3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)amino)etanol; cis-4-(2-(1-(2-hidroxietil)-3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; cis-6-(5-(4-hidroxiciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-1-metilindolin-2-ona; cis-4-(2-(1-(2-metoxietil)-3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; cis-4-(2-(2-(hidroximetil)-1H-benzo[d]imidazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; cis-4-(2-(2-(metoximetil)-1H-benzo[d]imidazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; cis-4-(2-(1-etil-3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; cis-5-(5-(4-hidroxiciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-2-(2-hidroxietil)isoindolin-1-ona; trans-4-(2-(3-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; cis-6-(5-(4-hidroxiciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-3,3-dimetilindolin-2-ona; cis-6-(5-(4-hidroxiciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-3,4-dihidroisoquinolin-1(2H)-ona; cis-4-(2-(4-metil-1H-indazol-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; cis-6-(5-(4-hidroxiciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-2-(2-hidroxietil)isoindolin-1-ona; N2-(3-metil-1H-indazol-6-il)-N5-(tetrahidro-2H-piran-4-il)-[1,2,4]triazolo[1,5-a]piridin-2,5-diamina; cis-4-(2-(4-fluoro-3-(2-metoxietoxi)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol;340imagen10 imagen11 imagen12 imagen13 6-(5-(isopropilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-3,3-dimetilindolin-2-ona; N2-(1-metil-1H-indazol-5-il)-N5-(tetrahidro-2H-piran-4-il)-[1,2,4]triazolo[1,5-a]piridin-2,5-diamina; cis-4-(2-(1H-pirazolo[4,3-b]piridin-6-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; cis-4-(5-(4-hidroxiciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-1,6-dimetilindolin-2-ona; cis-6-(5-(4-hidroxiciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-1,4-dimetilindolin-2-ona; 4-(5-(ciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)benzamida; N2-(4-(1H-1,2,4-triazol-3-il)fenil)-N5-(tetrahidro-2H-piran-4-il)-[1,2,4]triazolo[1,5-a]piridin-2,5-diamina; 6-(5-(dimetilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-3,3-dimetilindolin-2-ona; cis-4-(2-(4-(1H-1,2,4-triazol-3-il)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; cis-4-(2-(3-metil-[1,2,4]triazolo[4,3-a]piridin-7-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-ilamino)ciclohexanol; 1-metil-5-(5-(tetrahidro-2H-piran-4-ilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-1H-benzo[d]imidazol-2(3H)ona;o cis-5-(5-(4-hidroxiciclohexilamino)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-1-metil-1H-benzo[d]imidazol-2(3H)ona. - 14. Un compuesto o una sal, tautómero, estereoisómero o solvato farmacéuticamente aceptable del mismo, en donde el compuesto es N-metil-4-(5-(2-metil-1H-benzo[d]imidazol-6-il)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)benzamida; 5-(5-(2-(hidroximetil)-1H-benzo[d]imidazol-6-il)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)piridin-2-ol; (6-(2-(6-metoxipiridin-3-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)-1H-benzo[d]imidazol-2-il)metanol; (6-(2-(6-metilpiridin-3-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)-1H-benzo[d]imidazol-2-il)metanol; (6-(2-(6-(dimetilamino)piridin-3-ilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)-1H-benzo[d]imidazol-2-il)metanol; 2-(6-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)-1H-benzo[d]imidazol-2-il)propan-2-ol; 5-(2-(metoximetil)-1H-benzo[d]imidazol-6-il)-N-(4-(trifluorometil)fenil)-[1,2,4]triazolo[1,5a]piridin-2-amina; 1-(6-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)-1H-benzo[d]imidazol-2-il)etanol; 6-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)1H-benzo[d]imidazol-2-carboxamida; (6-(2-(4-(trifluorometil)fenilamino)-[1,2,4]triazolo[1,5-a]piridin-5-il)-1H-benzo[d]imidazol-2-il)metanol; 5-(2-((metilamino)metil)benzo[d]oxazol-6-il)-N-fenil-[1,2,4]triazolo[1,5-a]piridin-2-amina; 4-(5-(1H-indazol-5-il)-[1,2,4]triazolo[1,5-a]piridin-2-ilamino)-N-metilbenzamida; N-fenil-5-(2-(pirrolidin-1-ilmetil)-1H-benzo[d]imidazol-6-il)-[1,2,4]triazolo[1,5-a]piridin-2-amina; 5-(4-metilisoxazol-3-il)-N-fenil-[1,2,4]triazolo[1,5-a]piridin-2-amina; N-(4-fluorofenil)-5-(1H-indazol-6-il)-[1,2,4]triazolo[1,5-a]piridin-2-amina; N-(4-fluorofenil)-5-(2-((metilamino)metil)-1H-benzo[d]imidazol-6-il)-[1,2,4]triazolo[1,5-a]piridin-2-amina; 5-(3-amino-1H-indazol-6-il)-N-fenil-[1,2,4]triazolo[1,5-a]piridin-2-amina; 5-(2-((metilamino)metil)-1H-benzo[d]imidazol-6-il)-N-(4-(trifluorometil)fenil)-[1,2,4]triazolo[1,5-a]piridin-2-amina; 5-(5-metilisoxazol-3-il)-N-fenil-[1,2,4]triazolo[1,5-a]piridin-2-amina; 5-(2-(metilamino)-1H-benzo[d]imidazol-5-il)-N-fenil-[1,2,4]triazolo[1,5-a]piridin-2-amina;5-(1H-indazol-6-il)-N-fenil-[1,2,4]triazolo[1,5-a]piridin-2-amina; 5-(2-((dimetilamino)metil)-1H-benzo[d]imidazol-5-il)-N-fenil-[1,2,4]triazolo[1,5-a]piridin-2-amina;345
imagen14 imagen15 imagen16 imagen17 en donde la afección inmunológica es el síndrome de Behcet, la enfermedad mastocitaria no alérgica, la espondilitis anquilosante, la osteoartritis, la artritis reumatoide, la esclerosis múltiple, el lupus, la enfermedad inflamatoria del intestino, la colitis ulcerosa, la enfermedad de Crohn, la miastenia grave, la enfermedad de Grave, el rechazo de trasplantes, el rechazo humoral de trasplantes, el rechazo no humoral de trasplantes, el 5 rechazo celular de trasplantes, la púrpura trombocitopénica inmune, la púrpura trombocitopénica idiopática, la diabetes, la respuesta inmunológica a la infestación bacteriana, parasitaria, helmíntica o a la infección viral, el eccema, la dermatitis, la enfermedad de injerto contra hospedador, la enfermedad de Goodpasture, la enfermedad hemolítica del recién nacido, la anemia hemolítica autoinmune, el síndrome antifosfolipídico, la vasculitis asociada a ANCA, el síndrome de Churg-Strauss, la granulomatosis de Wegener, el pénfigo vulgar, la10 enfermedad del suero, la crioglobulinemia mixta, la neuropatía periférica asociada al anticuerpo IgM, la poliangitis microscópica, la tiroiditis de Hashimoto, el síndrome de Sjogren, una afección fibrótica o la cirrosis biliar primaria; oen donde la afección inflamatoria es la vasculitis no-ANCA, la psoriasis, el asma, la rinitis alérgica, la conjuntivitis alérgica, la urticaria crónica, la urticaria, la anafilaxia, la bronquitis, la enfermedad pulmonar obstructiva crónica,15 la fibrosis quística, la enfermedad inflamatoria del intestino, el síndrome del intestino irritable, la gota, la enfermedad de Crohn, la colitis mucosa, la colitis ulcerosa, la alergia a un antígeno intestinal, la diabetes o la obesidad; oen donde la enfermedad cardiovascular es la reestenosis, la aterosclerosis, el accidente cerebrovascular, el infarto de miocardio, el daño isquémico al corazón, pulmón, intestino, riñón, hígado, páncreas, bazo o cerebro; o20 en donde la enfermedad neurodegenerativa o neuroinflamatoria es la enfermedad de Huntington, la enfermedad de Alzheimer, o la encefalitis o el daño asociados a virus o bacterias.350
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9521708P | 2008-09-08 | 2008-09-08 | |
| US95217P | 2008-09-08 | ||
| US23047909P | 2009-07-31 | 2009-07-31 | |
| US230479P | 2009-07-31 | ||
| PCT/US2009/005020 WO2010027500A1 (en) | 2008-09-08 | 2009-09-08 | Aminotriazolopyridines and their use as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2581565T3 true ES2581565T3 (es) | 2016-09-06 |
Family
ID=41228355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09789271.5T Active ES2581565T3 (es) | 2008-09-08 | 2009-09-08 | Aminotriazolopiridinas y su uso como inhibidores de cinasas |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8299056B2 (es) |
| EP (1) | EP2344494B1 (es) |
| JP (1) | JP5689060B2 (es) |
| KR (1) | KR20110053266A (es) |
| CN (2) | CN104910148B (es) |
| AU (1) | AU2009288618B2 (es) |
| BR (1) | BRPI0918854A2 (es) |
| CA (1) | CA2735806A1 (es) |
| CL (1) | CL2011000480A1 (es) |
| CO (1) | CO6531502A2 (es) |
| CR (1) | CR20110132A (es) |
| EC (1) | ECSP11010945A (es) |
| ES (1) | ES2581565T3 (es) |
| IL (1) | IL211549A (es) |
| MX (1) | MX2011002536A (es) |
| NI (1) | NI201100048A (es) |
| NZ (1) | NZ591551A (es) |
| PE (1) | PE20110387A1 (es) |
| RU (1) | RU2552642C2 (es) |
| TW (1) | TWI453207B (es) |
| WO (1) | WO2010027500A1 (es) |
| ZA (1) | ZA201101586B (es) |
Families Citing this family (142)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60100852A (ja) * | 1984-09-28 | 1985-06-04 | Hitachi Ltd | 情報伝送方法 |
| ZA200701232B (en) | 2004-07-15 | 2008-08-27 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| CA2714414A1 (en) | 2008-02-13 | 2009-08-20 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| CA2713716A1 (en) | 2008-02-22 | 2009-08-27 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| JP5595389B2 (ja) * | 2008-06-20 | 2014-09-24 | ジェネンテック， インコーポレイテッド | トリアゾロピリジンｊａｋ阻害剤化合物と方法 |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| WO2010040661A1 (en) | 2008-10-09 | 2010-04-15 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| KR101293421B1 (ko) | 2008-11-10 | 2013-08-05 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 감마 분비효소 조절제 |
| TWI478922B (zh) | 2008-12-08 | 2015-04-01 | Gilead Connenticut Inc | 作為脾臟酪胺酸激酶（Ｓｙｋ）抑制劑之咪唑並吡化合物 |
| CN102307581B (zh) | 2008-12-08 | 2016-08-17 | 吉利德康涅狄格股份有限公司 | 咪唑并哌嗪syk抑制剂 |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| AU2011211410B2 (en) * | 2009-02-13 | 2013-01-31 | Fovea Pharmaceuticals Sa | [1,2,4] triazolo [1,5-A] pyridines as kinase inhibitors |
| CA2751517A1 (en) * | 2009-02-13 | 2010-08-19 | Fovea Pharmaceuticals | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
| CA2760837C (en) | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
| WO2010132437A1 (en) | 2009-05-12 | 2010-11-18 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| JP5739415B2 (ja) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用 |
| TWI546537B (zh) * | 2009-05-19 | 2016-08-21 | 維維亞生技公司 | 提供針對血液腫瘤之體外個人化藥物測試之方法 |
| EP2438066A2 (en) | 2009-06-05 | 2012-04-11 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES |
| EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| SI2516434T1 (sl) | 2009-12-23 | 2015-10-30 | Takeda Pharmaceutical Company Limited | Zliti heteroaromatski pirolidinoni kot inhibitorji SYK |
| US20110190269A1 (en) * | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| US9205577B2 (en) * | 2010-02-05 | 2015-12-08 | Allergan, Inc. | Porogen compositions, methods of making and uses |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| US9562056B2 (en) | 2010-03-11 | 2017-02-07 | Gilead Connecticut, Inc. | Imidazopyridines Syk inhibitors |
| US11202853B2 (en) * | 2010-05-11 | 2021-12-21 | Allergan, Inc. | Porogen compositions, methods of making and uses |
| TW201204723A (en) | 2010-06-22 | 2012-02-01 | Fovea Pharmaceuticals | Heterocyclic compounds, their preparation and their therapeutic application |
| AU2011270701B2 (en) * | 2010-06-24 | 2015-05-14 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| MX2013002198A (es) | 2010-08-27 | 2013-03-18 | Merck Patent Gmbh | Derivados de triazolopirazina. |
| KR20130108318A (ko) | 2010-08-27 | 2013-10-02 | 메르크 파텐트 게엠베하 | 푸로피리딘 유도체들 |
| CN102101841B (zh) * | 2010-12-06 | 2013-04-03 | 周玉莲 | 一种2-氯-4-氨基吡啶的合成制备方法 |
| EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
| WO2012121957A1 (en) * | 2011-03-08 | 2012-09-13 | Glaxosmithkline Llc | Combination |
| TWI548621B (zh) | 2011-04-22 | 2016-09-11 | 標誌製藥公司 | 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法 |
| EP2706852B1 (en) | 2011-05-10 | 2018-08-22 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
| EP2707357B1 (en) | 2011-05-10 | 2017-01-18 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
| KR20140028062A (ko) | 2011-05-10 | 2014-03-07 | 머크 샤프 앤드 돔 코포레이션 | Syk 억제제로서의 아미노피리미딘 |
| WO2012163724A1 (en) * | 2011-05-31 | 2012-12-06 | F. Hoffmann-La Roche Ag | Triazolopyridine compounds |
| US9056873B2 (en) | 2011-06-22 | 2015-06-16 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| AR087609A1 (es) | 2011-08-23 | 2014-04-03 | Syngenta Participations Ag | Microbiocidas |
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| EP2763975B1 (en) | 2011-10-05 | 2016-04-06 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| EP2763976B1 (en) | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| EP2763974B1 (en) | 2011-10-05 | 2016-09-14 | Merck Sharp & Dohme Corp. | Phenyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| WO2013124025A1 (en) | 2012-02-21 | 2013-08-29 | Merck Patent Gmbh | Furopyridine derivatives |
| ES2674451T3 (es) | 2012-02-21 | 2018-06-29 | Merck Patent Gmbh | 2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2 |
| US20150051202A1 (en) * | 2012-03-07 | 2015-02-19 | Merck Patent Gmbh | Triazolopyrazine derivatives |
| AR090650A1 (es) | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo |
| CN103450068B (zh) * | 2012-05-27 | 2015-09-16 | 重庆常捷医药化工有限公司 | 一种齐拉西酮中间体的合成方法 |
| US9242984B2 (en) | 2012-06-20 | 2016-01-26 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as Syk inhibitors |
| WO2013192128A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
| PL2863950T3 (pl) * | 2012-06-22 | 2019-02-28 | Galapagos Nv | Aminotriazolopirydyna do zastosowania w leczeniu zapalenia i jej kompozycje farmaceutyczne |
| ES2618004T3 (es) | 2012-08-07 | 2017-06-20 | Merck Patent Gmbh | Derivados de piridopirimidina como inhibidores de proteínas quinasas |
| AU2013315643B2 (en) * | 2012-09-14 | 2016-11-17 | Corteva Agriscience Llc | An improved process for the preparation of 2-amino-5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidine from 4-amino-2,5-dimethoxypyrimidine |
| US9586931B2 (en) | 2012-09-28 | 2017-03-07 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as Syk inhibitors |
| TWI692469B (zh) | 2012-11-09 | 2020-05-01 | 南韓商Ｌｇ化學股份有限公司 | Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
| WO2014093191A1 (en) | 2012-12-12 | 2014-06-19 | Merck Sharp & Dohme Corp. | AMINO-PYRIMIDINE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| EP2934525B1 (en) | 2012-12-21 | 2019-05-08 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
| RU2538086C2 (ru) * | 2013-01-29 | 2015-01-10 | Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Новосибирский Государственный Педагогический Университет" | Способ лечения сахарного диабета, осложненного сопутствующими заболеваниями |
| WO2014121450A1 (zh) * | 2013-02-05 | 2014-08-14 | Wang Dongjun | 卷对卷式原子层沉积设备及其使用方法 |
| US10130609B2 (en) | 2013-03-13 | 2018-11-20 | University Health Network | Pyrazole derivatives and their uses thereof |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| EP2989080A1 (en) | 2013-04-22 | 2016-03-02 | Reuter Chemische Apparatebau KG | Process for preparing enantiomerically enriched 3-hydroxymethylpiperidine |
| WO2014176216A1 (en) | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
| WO2014176210A1 (en) | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| EP3004095A1 (de) * | 2013-06-03 | 2016-04-13 | Bayer Pharma Aktiengesellschaft | Triazolopyridine als thrombininhibitoren zur behandlung von thromboembolischen erkrankungen |
| WO2014195276A1 (en) * | 2013-06-07 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines having activity as mps-1 inhibitors |
| CA2914668A1 (en) * | 2013-06-10 | 2014-12-18 | Volker Schulze | Novel compounds for the treatment of cancer |
| AR096654A1 (es) | 2013-06-20 | 2016-01-27 | Ab Science | Derivados de benzimidazol como inhibidores selectivos de proteína quinasa |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| MD4684B1 (ro) | 2013-07-30 | 2020-03-31 | Gilead Connecticut INc. | Formulări pe bază de imidazopirazine în calitate de inhibitori SYK |
| US20160168155A1 (en) | 2013-07-30 | 2016-06-16 | Gilead Connecticut, Inc. | Polymorph of syk inhibitors |
| AU2014296184B2 (en) | 2013-07-31 | 2017-04-27 | Gilead Sciences, Inc. | Syk inhibitors |
| WO2015026851A1 (en) * | 2013-08-20 | 2015-02-26 | Olatec Industries Llc | Pharmaceutical composition and use of diethyl (2-cyanoethyl)phosphonate |
| CN105745209B (zh) * | 2013-09-05 | 2018-10-23 | 豪夫迈·罗氏有限公司 | 三唑并吡啶化合物、组合物及其使用方法 |
| WO2015084992A1 (en) | 2013-12-04 | 2015-06-11 | Gilead Sciences, Inc. | Methods for treating cancers |
| EP3083559B1 (en) | 2013-12-20 | 2021-03-10 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| WO2015094997A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| WO2015095444A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| UY35898A (es) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ?compuestos inhibidores de syk y composiciones que los comprenden?. |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| US9775839B2 (en) | 2014-03-13 | 2017-10-03 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
| JP6416275B2 (ja) | 2014-03-19 | 2018-10-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ヘテロアリールｓｙｋ阻害剤 |
| WO2015157955A1 (en) | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
| JP6310144B2 (ja) | 2014-07-14 | 2018-04-18 | ギリアード サイエンシーズ， インコーポレイテッド | がんを処置するための組み合わせ |
| KR20170095814A (ko) | 2014-10-06 | 2017-08-23 | 플랫틀리 디스커버리 랩, 엘엘씨 | 트라이아졸로피리딘 화합물 및 낭성 섬유증의 치료 방법 |
| EP3262028B1 (en) | 2014-12-17 | 2021-10-27 | Pimco 2664 Limited | N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| US10252981B2 (en) | 2015-07-24 | 2019-04-09 | Celgene Corporation | Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
| CN104974085A (zh) * | 2015-07-24 | 2015-10-14 | 陈吉美 | 一种2-氯-4-氨基吡啶的制备方法 |
| CN108289861B (zh) * | 2015-08-03 | 2021-11-02 | 大日本住友制药肿瘤公司 | 用于治疗癌症的组合疗法 |
| CN105237480B (zh) * | 2015-08-14 | 2017-12-05 | 三峡大学 | 一种2‑三氟甲基苯并咪唑化合物及其制备方法 |
| EA033978B1 (ru) | 2015-09-11 | 2019-12-16 | Бёрингер Ингельхайм Интернациональ Гмбх | Пиразолилзамещенные гетероарилы и их применение в качестве лекарственных средств |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CN105198881B (zh) * | 2015-09-23 | 2017-12-15 | 上海泰坦科技股份有限公司 | 5‑溴‑3‑甲基‑1h‑吡唑并[3,4‑b]吡啶的合成工艺 |
| CN105664178B (zh) * | 2015-09-24 | 2019-08-20 | 洪健 | Syk作为肝纤维化/硬化治疗靶点的应用 |
| CA3001799A1 (en) | 2015-10-21 | 2017-04-27 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| CN105596333A (zh) * | 2016-02-02 | 2016-05-25 | 白强 | 一种防治糖尿病及其并发症的药物组合物及其应用 |
| CN105622485B (zh) * | 2016-03-01 | 2019-05-03 | 苏州艾缇克药物化学有限公司 | 一种无机催化剂催化合成3，3’-氧化吲哚的方法 |
| CN105646234A (zh) * | 2016-03-23 | 2016-06-08 | 叶芳 | 一种2-溴-5-硝基苯胺及其制备方法 |
| WO2017167953A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| EP3475279B1 (en) * | 2016-06-27 | 2021-07-14 | F. Hoffmann-La Roche AG | Triazolopyridines as gamma-secretase modulators |
| CN106117202B (zh) * | 2016-06-29 | 2018-06-26 | 四川大学华西医院 | 具有抗肿瘤活性的[1,2,4]三唑并[1,5-a]吡啶衍生物晶型 |
| WO2018000549A1 (zh) * | 2016-06-29 | 2018-01-04 | 四川大学华西医院 | [1,2,4]三唑并[1,5-a]吡啶衍生物及其晶型 |
| TW201822764A (zh) | 2016-09-14 | 2018-07-01 | 美商基利科學股份有限公司 | Syk抑制劑 |
| EP3512519A1 (en) | 2016-09-14 | 2019-07-24 | Gilead Sciences, Inc. | Syk inhibitors |
| CN109963851B (zh) * | 2016-10-26 | 2021-11-30 | 詹森药业有限公司 | 融合的双环吡啶化合物及其作为ampa受体调节剂的用途 |
| CN108017573B (zh) * | 2016-11-01 | 2021-03-26 | 山东特珐曼药业有限公司 | 4-亚甲基哌啶或其酸加成盐的制备方法 |
| WO2018082441A1 (zh) * | 2016-11-01 | 2018-05-11 | 山东特珐曼药业有限公司 | 4-亚甲基哌啶或其酸加成盐的制备方法 |
| CA3043708A1 (en) * | 2016-11-17 | 2018-05-24 | Cleveland State University | Chip platforms for microarray 3d bioprinting |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| WO2018195471A1 (en) | 2017-04-21 | 2018-10-25 | Gilead Sciences, Inc. | Syk inhibitors in combination with hypomethylating agents |
| BR112019022831A2 (pt) | 2017-05-02 | 2020-05-26 | Bayer Aktiengesellschaft | Derivados heterocíclicos bicíclicos condensados substituídos por 2-(het)arila como agentes de controle de praga |
| JP7119003B2 (ja) | 2017-05-02 | 2022-08-16 | バイエル・アクチエンゲゼルシヤフト | 有害生物防除剤としての２－（ヘタ）アリール置換縮合二環式ヘテロ環式誘導体 |
| PE20200342A1 (es) | 2017-05-22 | 2020-02-14 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue |
| ES2929667T3 (es) | 2017-05-22 | 2022-11-30 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
| CN115028640A (zh) | 2017-08-25 | 2022-09-09 | 吉利德科学公司 | Syk抑制剂的多晶型物 |
| JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| UY38051A (es) * | 2018-01-17 | 2019-08-30 | Glaxosmithkline Ip Dev Ltd | INHIBIDORES DE LA PI4KIIIß |
| CN108572224A (zh) * | 2018-04-25 | 2018-09-25 | 滨州医学院 | 一种生物组织中丙二醛含量的测定方法 |
| WO2020030754A1 (en) | 2018-08-10 | 2020-02-13 | Syngenta Crop Protection Ag | Pesticidally-active mesoionic bicyclic heteroaromatic compounds |
| GB201813312D0 (en) | 2018-08-15 | 2018-09-26 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| WO2020035565A1 (en) | 2018-08-17 | 2020-02-20 | Syngenta Crop Protection Ag | Pesticidally-active mesoionic bicyclic heteroaromatic compounds |
| MX2021006544A (es) | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. |
| JP2022521413A (ja) | 2019-02-22 | 2022-04-07 | クロノス バイオ インコーポレイテッド | Ｓｙｋ阻害剤としての縮合ピラジンの固体形態 |
| WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
| FR3096048B1 (fr) * | 2019-05-16 | 2021-04-30 | Arkema France | Procede ameliore de preparation d'hydrate d'hydrazine avec recyclage oxime |
| EP4011880A4 (en) * | 2019-08-06 | 2023-09-13 | Jiangsu Carephar Pharmaceutical Co., Ltd | JAK KINASE INHIBITOR AND USE THEREOF |
| CN110981854B (zh) * | 2019-09-10 | 2023-03-28 | 南京三元阳普医药科技有限公司 | 2-氨基-6-(1-烷基哌啶-4-羰基)吡啶类化合物的合成方法 |
| WO2022140520A1 (en) * | 2020-12-24 | 2022-06-30 | Escient Pharmaceuticals, Inc. | Modulators of mas-related g-protein receptor x2 and related products and methods |
| CN113583110B (zh) * | 2021-08-19 | 2023-07-21 | 华南农业大学 | 一种苯并三唑半抗原、人工抗原和抗体及其制备方法与应用 |
| CN113801152B (zh) * | 2021-08-30 | 2023-08-11 | 上海日异生物科技有限公司 | 3-羧基-5-羟基苯硼酸的合成方法 |
| CN115819425A (zh) * | 2022-12-22 | 2023-03-21 | 五邑大学 | 一种三唑并六元氮杂环-2-胺类化合物及其制备方法和应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57206685A (en) | 1981-06-16 | 1982-12-18 | Kyorin Pharmaceut Co Ltd | Novel triazolo pyridine derivative |
| JPH04190232A (ja) | 1990-11-26 | 1992-07-08 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| WO1992016497A1 (en) | 1991-03-22 | 1992-10-01 | Japan Tobacco Inc. | Amino acid derivative having renin inhibitory activity |
| DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| JP2878531B2 (ja) | 1991-12-16 | 1999-04-05 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料 |
| AR015104A1 (es) | 1996-11-13 | 2001-04-18 | Dowelanco | Compuestos de n-arilsulfilimina sustituidos, utiles como catalizadores en la preparacion de compuestos de n-arilarilsulfonamida; proceso para preparar dichos compuestos y su uso para catalizar dicha preparacion. |
| CN1243514A (zh) | 1997-01-11 | 2000-02-02 | 财团法人韩国化学研究所 | 磺胺衍生物 |
| US6355653B1 (en) * | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| PL370067A1 (en) * | 2001-10-08 | 2005-05-16 | F.Hoffmann-La Roche Ag | 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide |
| US20030158195A1 (en) * | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
| JP4190232B2 (ja) | 2002-08-26 | 2008-12-03 | 富士通株式会社 | 機械研磨を行う方法 |
| OA12925A (en) | 2002-09-18 | 2006-10-13 | Pfizer Prod Inc | Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors. |
| TWI335913B (en) * | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| WO2006018735A2 (en) | 2004-08-18 | 2006-02-23 | Pharmacia & Upjohn Company Llc | Triazolopyridine compounds |
| US7524860B2 (en) | 2004-10-07 | 2009-04-28 | Pfizer Inc. | Antibacterial agents |
| JP2009538877A (ja) | 2006-05-31 | 2009-11-12 | ガラパゴス・ナムローゼ・フェンノートシャップ | 変性疾患及び炎症性疾患の治療に有用なトリアゾロピラジン化合物 |
| EP1894931A1 (en) * | 2006-08-30 | 2008-03-05 | Cellzome Ag | Triazole derivatives as kinase inhibitors |
| SG174086A1 (en) * | 2006-08-30 | 2011-09-29 | Cellzome Ltd | Triazole derivatives as kinase inhibitors |
| GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| FR2928924B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique |
| US7863291B2 (en) * | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| JP5512665B2 (ja) | 2008-06-20 | 2014-06-04 | ジェネンテック， インコーポレイテッド | トリアゾロピリジンｊａｋ阻害剤化合物と方法 |
| JP5595389B2 (ja) * | 2008-06-20 | 2014-09-24 | ジェネンテック， インコーポレイテッド | トリアゾロピリジンｊａｋ阻害剤化合物と方法 |
| WO2010010189A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010188A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
-
2009
- 2009-09-07 TW TW098130164A patent/TWI453207B/zh not_active IP Right Cessation
- 2009-09-08 ES ES09789271.5T patent/ES2581565T3/es active Active
- 2009-09-08 MX MX2011002536A patent/MX2011002536A/es active IP Right Grant
- 2009-09-08 PE PE2011000599A patent/PE20110387A1/es not_active Application Discontinuation
- 2009-09-08 EP EP09789271.5A patent/EP2344494B1/en active Active
- 2009-09-08 BR BRPI0918854-1A patent/BRPI0918854A2/pt not_active IP Right Cessation
- 2009-09-08 JP JP2011526054A patent/JP5689060B2/ja not_active Expired - Fee Related
- 2009-09-08 NZ NZ591551A patent/NZ591551A/en not_active IP Right Cessation
- 2009-09-08 WO PCT/US2009/005020 patent/WO2010027500A1/en active Application Filing
- 2009-09-08 AU AU2009288618A patent/AU2009288618B2/en not_active Ceased
- 2009-09-08 CN CN201510173699.6A patent/CN104910148B/zh not_active Expired - Fee Related
- 2009-09-08 RU RU2011113540/04A patent/RU2552642C2/ru not_active IP Right Cessation
- 2009-09-08 CN CN200980144169.1A patent/CN102203093B/zh not_active Expired - Fee Related
- 2009-09-08 KR KR1020117007996A patent/KR20110053266A/ko active Search and Examination
- 2009-09-08 US US12/555,018 patent/US8299056B2/en active Active
- 2009-09-08 CA CA2735806A patent/CA2735806A1/en not_active Abandoned
-
2011
- 2011-03-01 ZA ZA2011/01586A patent/ZA201101586B/en unknown
- 2011-03-03 IL IL211549A patent/IL211549A/en not_active IP Right Cessation
- 2011-03-07 NI NI201100048A patent/NI201100048A/es unknown
- 2011-03-07 CL CL2011000480A patent/CL2011000480A1/es unknown
- 2011-03-11 CR CR20110132A patent/CR20110132A/es unknown
- 2011-04-01 EC EC2011010945A patent/ECSP11010945A/es unknown
- 2011-04-05 CO CO11041595A patent/CO6531502A2/es not_active Application Discontinuation
-
2012
- 2012-09-11 US US13/609,412 patent/US20130005707A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL211549A0 (en) | 2011-05-31 |
| BRPI0918854A2 (pt) | 2019-02-26 |
| WO2010027500A1 (en) | 2010-03-11 |
| EP2344494B1 (en) | 2016-04-20 |
| JP2012502029A (ja) | 2012-01-26 |
| CO6531502A2 (es) | 2012-09-28 |
| RU2011113540A (ru) | 2012-10-20 |
| CN104910148A (zh) | 2015-09-16 |
| CN102203093A (zh) | 2011-09-28 |
| CA2735806A1 (en) | 2010-03-11 |
| CN104910148B (zh) | 2017-06-27 |
| KR20110053266A (ko) | 2011-05-19 |
| IL211549A (en) | 2017-04-30 |
| ZA201101586B (en) | 2012-05-30 |
| EP2344494A1 (en) | 2011-07-20 |
| RU2552642C2 (ru) | 2015-06-10 |
| NZ591551A (en) | 2011-10-28 |
| TWI453207B (zh) | 2014-09-21 |
| US8299056B2 (en) | 2012-10-30 |
| CN102203093B (zh) | 2015-05-13 |
| PE20110387A1 (es) | 2011-06-22 |
| JP5689060B2 (ja) | 2015-03-25 |
| AU2009288618B2 (en) | 2014-10-02 |
| AU2009288618A1 (en) | 2010-03-11 |
| ECSP11010945A (es) | 2011-05-31 |
| NI201100048A (es) | 2011-11-17 |
| TW201024293A (en) | 2010-07-01 |
| US20100093698A1 (en) | 2010-04-15 |
| CR20110132A (es) | 2011-06-20 |
| CL2011000480A1 (es) | 2011-09-16 |
| MX2011002536A (es) | 2011-04-04 |
| US20130005707A1 (en) | 2013-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2581565T3 (es) | Aminotriazolopiridinas y su uso como inhibidores de cinasas | |
| RU2009120882A (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
| JP5466246B2 (ja) | Ｃｃｒ３アンタゴニストとしての置換ピペリジン | |
| EP2566477B1 (en) | Amino-quinolines as kinase inhibitors | |
| AU2005304393B2 (en) | IL-12 modulatory compounds | |
| JP4688876B2 (ja) | タンパク質キナーゼ阻害剤としての化合物および組成物 | |
| RU2013124101A (ru) | Гетероциклические амины и их применения | |
| US8268850B2 (en) | Pyrimidine derivatives and compositions as C-kit and PDGFR kinase inhibitors | |
| JP2018109038A (ja) | Ｌｒｒｋ２調節薬としてのピラゾールアミノピリミジン誘導体 | |
| EP2603218B1 (en) | Quinolyl amines as kinase inhibitors | |
| CN1950082A (zh) | 双环和桥连的含氮杂环化物 | |
| JP2013544256A5 (es) | ||
| CN1658866A (zh) | 三取代的杂芳基以及制备方法和其用途 | |
| JP2019535728A (ja) | キナーゼ阻害剤としての複素環式アミド | |
| WO2011120025A1 (en) | Indazolyl-pyrimidines as kinase inhibitors | |
| CA2606004A1 (en) | Dipiperazinyl ketones and related analogues | |
| NO20084832L (no) | Pyrimidinderivater som P13K-inhibitorer | |
| JP2011518836A5 (es) | ||
| WO2012142329A1 (en) | Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors | |
| JP2015523387A (ja) | ロイコトリエン生成を阻害するピラゾール誘導体 | |
| CN105814061A (zh) | 作为tnf活性调节剂的咪唑并哒嗪衍生物 | |
| JP2010526793A (ja) | Ｐ２ｘ７調節因子としてのピラゾール誘導体 | |
| HRP20211678T1 (hr) | N-supstituirani derivati indola kao modulatori receptora pge2 | |
| RU2014119244A (ru) | Гетероциклические соединения и способы их использования | |
| EA023237B1 (ru) | Производные гетероциклических аминов |